Business
Homology Medicines Reports First Quarter 2020 Financial Results and Recent Highlights
- Progressed the pheNIX Trial for PKU and Added Clinical Sites, Completed Clinical Supply for Phase 1/2 and Began Manufacturing Pivotal Supply - - Executed
About this update from Q32 Bio Inc.
[{"type":"text","content":"- Progressed the pheNIX Trial for PKU and Added Clinical Sites, Completed Clinical Supply for Phase 1/2 and Began Manufacturing Pivotal Supply - \n - Executed Commercial Manufacturing Process at 2,000-Liter Bioreactor Scale - - Implemented Plans to Minimize Potential COVID-19 Impact on Employees and Operations - BEDFORD, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the first quarter ended March 31, 2020, and highlighted recent accomplishments. “The Homology team’s experience, agility, and forward-thinking capabilities are a tremendous asset to the Company as we operate within this global health crisis, and as a result, our programs have continued to move forward,” stated Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines. “In taking proactive steps early on, we believe we were able to minimize the potential impact to our business by procuring sufficient raw materials, accelerating manufacturing and implementing safety measures for employees. In addition, we have established home-based care and monitoring services for patients in our Phase 1/2 pheNIX gene therapy trial for PKU, making their safety and continuity of the study priorities. We will continue to evaluate these measures and make adjustments as needed. Our plan is still to report additional data from our pheNIX clinical trial mid-year. Given the evolving nature of the COVID-19 pandemic, we will continue to work closely with trial sites in our efforts to achieve this goal.” Dr. Tzianabos concluded, “Our pipeline is also advancing, and we recently presented data further demonstrating the potential of our AAVHSC platform for diseases of the central and peripheral nervous systems. As leaders in the field of gene therapy and gene editing manufacturing, we expanded the internal capacity of our mammalian, suspension-based system to 1,500 liters, and we executed our commercial process at the 2,000-liter bioreactor scale.” First Quarter 2020 Financial Results and Recent Accomplishments Progressed the dose-escalation phase of the pheNIX clinical trial evaluating HMI-102 gene therapy for the treatment of adults with phenylketonuria (PKU). Following encouraging initial clinical data from the trial announced in December 2019, additional PKU centers ...